Search results
Showing 391 to 405 of 482 results for anxiety
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
Transperineal biopsy for diagnosing prostate cancer (HTG680)
Evidence-based recommendations on transperineal biopsy for diagnosing prostate cancer.
Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome in people aged 2 years and older.
Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)
Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults.
Cenobamate for treating focal onset seizures in epilepsy (TA753)
Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.
and carers (for outcomes such as experience of services, satisfaction and anxiety) may help to identify where improvements can be made...
be useful to validate generic measures (for example for depression and anxiety). People with a long-term physical health condition are...
NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .
Evidence-based recommendations on osimertinib (Tagrisso) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)
Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis.
Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)
Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.